Javascript must be enabled to continue!
The effect of co-treatment with DAPT and oxaliplatin on the biological behavior of human ovarian cancer stem cells
View through CrossRef
Abstract
To assess the effects of the combination of DAPT and oxaliplatin on the biological behavior of human ovarian cancer stem cells. In vitro cultured human ovarian cancer stem cells were randomly divided into DAPT, L-OHP, DAPT + L-OHP, and control groups. MTT assays were measured to assess the ability of inhibit proliferation. Inverted microscopy, flow cytometry, and in vitro invasion assays were performed to assess cell morphology, apoptosis, and cell invasion, respectively. Then, western blotting was used to detect Notch-1 and LRP1 expression in the four groups of cells. MTT assay revealed that DAPT and L-OHP monotherapy could inhibit the proliferation of ovarian cancer stem cells in a time- and dose-dependent manner. Inverted microscopy showed that untreated ovarian cancer stem cells had an oval or polygonal morphology, with a plump shape and large nuclei. After treatment with DAPT or L-OHP, cells shrank and cracked, with an irregular shape and increased shedding. Flow cytometry revealed that apoptosis was significantly higher in the DAPT and L-OHP groups compared with the control group; the DAPT + L-OHP group had a significantly higher rate of apoptosis than either the DAPT or L-OHP groups. An in vitro invasion assay revealed that DAPT + L-OHP inhibited cell invasion to a greater extent than either DAPT or L-OHP alone. Western blotting revealed that, compared with control, L-OHP had no effect on Notch-1 protein expression, whereas DAPT and DAPT + L-OHP significantly reduced Notch1 protein levels. In addition, cells treated with DAPT + L-OHP expressed much less Notch than those treated with DAPT alone. In the L-OHP group, LRP protein levels were increased significantly, whereas levels were decreased significantly in the DAPT and DAPT + L-OHP groups. DAPT inhibits the proliferation of ovarian cancer stem cells, promotes their apoptosis, weakens their invasive ability, and functions synergistically with L-OHP.
Title: The effect of co-treatment with DAPT and oxaliplatin on the biological behavior of human ovarian cancer stem cells
Description:
Abstract
To assess the effects of the combination of DAPT and oxaliplatin on the biological behavior of human ovarian cancer stem cells.
In vitro cultured human ovarian cancer stem cells were randomly divided into DAPT, L-OHP, DAPT + L-OHP, and control groups.
MTT assays were measured to assess the ability of inhibit proliferation.
Inverted microscopy, flow cytometry, and in vitro invasion assays were performed to assess cell morphology, apoptosis, and cell invasion, respectively.
Then, western blotting was used to detect Notch-1 and LRP1 expression in the four groups of cells.
MTT assay revealed that DAPT and L-OHP monotherapy could inhibit the proliferation of ovarian cancer stem cells in a time- and dose-dependent manner.
Inverted microscopy showed that untreated ovarian cancer stem cells had an oval or polygonal morphology, with a plump shape and large nuclei.
After treatment with DAPT or L-OHP, cells shrank and cracked, with an irregular shape and increased shedding.
Flow cytometry revealed that apoptosis was significantly higher in the DAPT and L-OHP groups compared with the control group; the DAPT + L-OHP group had a significantly higher rate of apoptosis than either the DAPT or L-OHP groups.
An in vitro invasion assay revealed that DAPT + L-OHP inhibited cell invasion to a greater extent than either DAPT or L-OHP alone.
Western blotting revealed that, compared with control, L-OHP had no effect on Notch-1 protein expression, whereas DAPT and DAPT + L-OHP significantly reduced Notch1 protein levels.
In addition, cells treated with DAPT + L-OHP expressed much less Notch than those treated with DAPT alone.
In the L-OHP group, LRP protein levels were increased significantly, whereas levels were decreased significantly in the DAPT and DAPT + L-OHP groups.
DAPT inhibits the proliferation of ovarian cancer stem cells, promotes their apoptosis, weakens their invasive ability, and functions synergistically with L-OHP.
Related Results
Stem cells
Stem cells
What is a stem cell? The term is a combination of ‘cell’ and ‘stem’. A cell is a major category of living thing, while a stem is a site of growth and support for something else. In...
Prolonging Dual Antiplatelet Therapy Improves Long-term Prognosis in Diabetic Patients Undergoing Complex Percutaneous Coronary Intervention with Drug-eluting Stents
Prolonging Dual Antiplatelet Therapy Improves Long-term Prognosis in Diabetic Patients Undergoing Complex Percutaneous Coronary Intervention with Drug-eluting Stents
Abstract
Background The optimal dual antiplatelet therapy (DAPT) duration after percutaneous coronary intervention (PCI) remains controversial, especially for patients at h...
Early dual antiplatelet therapy versus acetylsalicylic acid monotherapy after CABG: propensity score analysis addressing survival and safety outcomes
Early dual antiplatelet therapy versus acetylsalicylic acid monotherapy after CABG: propensity score analysis addressing survival and safety outcomes
Abstract
Background
There is currently conflicting evidence regarding the security profile and outcomes of dual antiplatelet the...
226 DUAL ANTI-PLATELET THERAPY: AUDIT OF COMMUNICATION OF DIAGNOSIS AND DURATION ACROSS PRIMARY AND SECONDARY CARE
226 DUAL ANTI-PLATELET THERAPY: AUDIT OF COMMUNICATION OF DIAGNOSIS AND DURATION ACROSS PRIMARY AND SECONDARY CARE
Abstract
Background
Dual Anti-Platelet Therapy (DAPT) is indicated in vascular disease & duration of treatment depends on fa...
Abstract IA31: Molecular epidemiology of ovarian cancer
Abstract IA31: Molecular epidemiology of ovarian cancer
Abstract
Epithelial ovarian cancer (EOC) accounts for 5% of all cancer deaths and is the fifth leading cause of cancer death in women in the United States. While the...
No Differences in Gastrointestinal Bleeding Risk among Clopidogrel-, Ticagrelor-, or Prasugrel-Based Dual Antiplatelet Therapy
No Differences in Gastrointestinal Bleeding Risk among Clopidogrel-, Ticagrelor-, or Prasugrel-Based Dual Antiplatelet Therapy
The risk for gastrointestinal bleeding from dual antiplatelet therapy (DAPT) with new antiplatelets (prasugrel/ticagrelor) compared to clopidogrel is unclear. Aim: To determine the...
Oxaliplatin resistance is enhanced by saracatinib via upregulation Wnt-ABCG1 signaling in hepatocellular carcinoma
Oxaliplatin resistance is enhanced by saracatinib via upregulation Wnt-ABCG1 signaling in hepatocellular carcinoma
Abstract
Background: Chemo-resistance in hepatocellular carcinoma (HCC) is a major problem, and acquired drug resistance prevents cancer therapies from achieving complete r...
Oxaliplatin resistance is enhanced by saracatinib via upregulation Wnt-ABCG1 signaling in hepatocellular carcinoma
Oxaliplatin resistance is enhanced by saracatinib via upregulation Wnt-ABCG1 signaling in hepatocellular carcinoma
Abstract
Background: Chemo-resistance in hepatocellular carcinoma (HCC) is a major problem, and acquired drug resistance prevents cancer therapies from achieving complete r...

